225 related articles for article (PubMed ID: 19346141)
1. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.
Fathallah H; Taher A; Bazarbachi A; Atweh GF
Blood Cells Mol Dis; 2009; 43(1):58-62. PubMed ID: 19346141
[TBL] [Abstract][Full Text] [Related]
2. Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
Perrine SP; Castaneda SA; Boosalis MS; White GL; Jones BM; Bohacek R
Ann N Y Acad Sci; 2005; 1054():257-65. PubMed ID: 16339673
[TBL] [Abstract][Full Text] [Related]
3. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Chou YC; Chen RL; Lai ZS; Song JS; Chao YS; Shen CK
Mol Cell Biol; 2015 Jul; 35(14):2541-53. PubMed ID: 25986606
[TBL] [Abstract][Full Text] [Related]
5. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
6. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy.
Ikuta T; Kan YW; Swerdlow PS; Faller DV; Perrine SP
Blood; 1998 Oct; 92(8):2924-33. PubMed ID: 9763579
[TBL] [Abstract][Full Text] [Related]
7. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia.
Perrine SP; Miller BA; Faller DV; Cohen RA; Vichinsky EP; Hurst D; Lubin BH; Papayannopoulou T
Blood; 1989 Jul; 74(1):454-9. PubMed ID: 2473801
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol-mediated reversion of γ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate for β-globin disorders.
Ali H; Khan F; Musharraf SG
Biomed Pharmacother; 2021 Oct; 142():112058. PubMed ID: 34426256
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
[TBL] [Abstract][Full Text] [Related]
10. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
Perrine SP; Olivieri NF; Faller DV; Vichinsky EP; Dover GJ; Ginder GD
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):67-71. PubMed ID: 7508690
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis.
Ikuta T; Atweh G; Boosalis V; White GL; Da Fonseca S; Boosalis M; Faller DV; Perrine SP
Ann N Y Acad Sci; 1998 Jun; 850():87-99. PubMed ID: 9668531
[TBL] [Abstract][Full Text] [Related]
12. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT
Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398
[TBL] [Abstract][Full Text] [Related]
13. Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors.
Palani CD; Zhu X; Alagar M; Attucks OC; Pace BS
Blood Cells Mol Dis; 2024 Jan; 104():102792. PubMed ID: 37633023
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
15. Butyrate in the treatment of sickle cell disease and beta-thalassemia.
Faller DV; Perrine SP
Curr Opin Hematol; 1995 Mar; 2(2):109-17. PubMed ID: 9371980
[TBL] [Abstract][Full Text] [Related]
16. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
Sher GD; Ginder GD; Little J; Yang S; Dover GJ; Olivieri NF
N Engl J Med; 1995 Jun; 332(24):1606-10. PubMed ID: 7753139
[TBL] [Abstract][Full Text] [Related]
17. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies.
Perrine SP; Pace BS; Faller DV
Hematol Oncol Clin North Am; 2014 Apr; 28(2):233-48. PubMed ID: 24589264
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.
Watanapokasin Y; Chuncharunee S; Sanmund D; Kongnium W; Winichagoon P; Rodgers GP; Fucharoen S
Exp Hematol; 2005 Dec; 33(12):1486-92. PubMed ID: 16338491
[TBL] [Abstract][Full Text] [Related]
19. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Fibach E; Prasanna P; Rodgers GP; Samid D
Blood; 1993 Oct; 82(7):2203-9. PubMed ID: 7691251
[TBL] [Abstract][Full Text] [Related]
20. Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line.
Zein S; Li W; Ramakrishnan V; Lou TF; Sivanand S; Mackie A; Pace B
Exp Biol Med (Maywood); 2010 Nov; 235(11):1385-94. PubMed ID: 20975082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
